BioSpace News Archive

Here are the top companies on BioSpace with internship opportunities for graduate students.

Ascidian Therapeutics, a member of BioSpace’s NextGen Class of 2024, on Monday announced it received IND clearance from the FDA and was granted Fast Track designation for ACDN-01.

MaxCyte, Inc. and Wugen, Inc. announced the signing of a strategic platform license.

Vaxxinity, Inc. today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases.

Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 December 2023 (Q2 FY24).

Bionano Genomics, Inc. (BNGO) today announced the conclusion of Bionano’s 2024 Symposium which was held January 22-25, 2024, and featured a record 32 oral presentations and 69 scientific posters from genomic scientists at leading institutions, including Brigham and Women’s Hospital, The University of Texas MD Anderson Cancer Center, Institute Curie, Memorial Sloan Kettering Cancer Center and Johns Hopkins University School of Medicine.

IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure” or the “Company”) today announced the U.S. Food and Drug Administration (“FDA”) has responded affirmatively to the Company’s request for supervisory review (“Appeal”) under 21 CFR 10.75 regarding the FDA’s prior denial of IceCure’s De Novo Classification Request for treating patients with early-stage, low risk breast cancer.

Akebia Therapeutics®, Inc. announced it has closed a loan facility with funds and accounts managed by BlackRock.

Abdera Therapeutics Inc. today announced the appointments of Philippe Bishop, M.D., as chief medical officer and Eric Dobmeier as a member of the company’s board of directors.